Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 125, Issue 11, Pages 2624-2630Publisher
WILEY-BLACKWELL
DOI: 10.1002/ijc.24639
Keywords
MIC-1/GDF15; prognostic biomarker; cerebrospinal fluid; glioblastoma
Categories
Funding
- Swiss National Science Foundation (SNSF) [3200BO-101231/1]
- Heim-Voegtlin Foundation
- Swiss Scholarship
- National Center of Competence in Research Molecular Oncology
Ask authors/readers for more resources
For patients with brain tumors identification of diagnostic and prognostic markers in easy accessible biological material, such as plasma or cerebrospinal fluid (CSF), would greatly facilitate patient management. MIC-1/GDF15 (growth differentiation factor 15) is a secreted protein of the TGF-beta superfamily and emerged as a candidate marker exhibiting increasing mRNA expression during malignant progression of glioma. Determination of MIC-1/GDF15 protein levels by ELISA in the CSF of a cohort of 94 patients with intracranial tumors including gliomas, meningioma and metastasis revealed significantly increased concentrations in glioblastoma patients (median, 229 pg/ml) when compared with control cohort of patients treated for non-neoplastic diseases (median below limit of detection of 156 pg/ml, p < 0.0001, Mann-Whitney test). However, plasma MIC-1/GDF15 levels were not elevated in the matching plasma samples from these patients. Most interestingly, patients with glioblastoma and increased CSF MIC-1/GDF15 had a shorter survival (p = 0.007, log-rank test). In conclusion, MIC-1/GDF15 protein measured in the CSF may have diagnostic and prognostic value in patients with intracranial tumors. (c) 2009 UICC
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available